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Influenza Vaccine Distribution Update
Influenza Vaccine Supply Update: Cumulative Doses of Influenza Vaccine Distributed 
by Month, by Season—United States, 2016-17 through 2019-20 Seasons
Influenza Vaccines for Older Adults—
WG Considerations
Abbreviations
IIV Inactivated Influenza Vaccine
ccIIV Cell culture based Inactivated Influenza Vaccine
aIIV Adjuvanted Inactivated Influenza Vaccine
HD-IIV High-Dose Inactivated Influenza Vaccine
RIV Recombinant Influenza Vaccine
LAIV Live Attenuated Influenza Vaccine
Numbers indicate the number of influenza virus antigens:
3 for trivalent: an A(H1N1), an A(H3N2), and one B (from one lineage)
4 for quadrivalent: an A(H1N1), an A(H3N2), and two Bs (one from each lineage)
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U.S. Seasonal Influenza Vaccines Since 2000-01
Number of unique products available by season
U.S.-Licensed Influenza Vaccines, 2019-20
Available vaccines by FDA-licensed age indication:
• ACIP recommends that a licensed, age-appropriate influenza vaccine should be used.
• No preferential recommendations are made for any specific influenza vaccine for any age group, where 
there is more than one that is appropriate.
Vaccine
type
6 through 23 
mos
2 through 3 
yrs
4 through 17 
yrs
18 through 49 
yrs
50 through 64 
yrs
≥65 yrs
IIV4s (egg-based) Afluria Quadrivalent 
Fluarix Quadrivalent
FluLaval Quadrivalent 
Fluzone Quadrivalent
IIV4 (cell-based) Flucelvax Quadrivalent
RIV4 (recombinant) Flublok Quadrivalent
Adjuvant IIV3 (egg-based) Fluad
High-dose IIV3 (egg-based) Fluzone High-dose
LAIV4 (egg-based) FluMist Quadrivalent
 Large variety of available influenza vaccines 
–
–
8 are appropriate for this age group by licensed indications
 Growing canon of studies comparing individual vaccine types, but data limited for 
some relevant comparisons
 Vaccine effectiveness (and relative effectiveness of different vaccines) varies from 
season to season
Cannot be certain that results from one or a few high-quality studies will 
generalize across all or most influenza seasons
Challenges in Assessing Relative Benefits of Specific 
Vaccines for Older Adults
HD-IIV3, aIIV3 and RIV4 for Older Adults
Study
Year published
Ages
Season(s) Comparison Design N Relative
Efficacy/effectiveness
DiazGranados 20131
≥65 years
1
2009-10
HD-IIV3 vs
SD-IIV3
RCT ~9,100 Not evaluable because of 
pandemic
DiazGranados 20142
≥65 years
2
2011-12, 2012-13
HD-IIV3 vs
SD-IIV3
RCT ~32,000 24.2% (95% CI = 9.7–36.5)
Dunkle 20173
≥50 years
1
2014-15
RIV4 vs
SD-IIV4
RCT ~8,600 30% (95% CI = 10–47) 
Van Buynder 20134
≥65 years
1
2011-12
aIIV3 vs
SD-IIV3
observational 227 63% (95% CI = 4–86)
Summary of studies examining laboratory-confirmed influenza outcomes:
1 DiazGranados CA et al, Vaccine 2013;31:861-866
2 DiazGranados CA et al, N Engl J Med 2014;371:635-645
3 Dunkle LM et al, N Engl J Med 2017;376:2427-2436
4 VanBuynder PG et al, Vaccine 2013; 31:6122-6128 
Do the relative benefits and harms of HD-IIV, aIIV, and RIV 
as compared with one another and with other influenza vaccines 
favor the use of these vaccines over others for persons aged 65 years and 
older?
Planned Systematic Review/Meta-analysis--Question
Population: Adults aged ≥65 years 
Interventions: Trivalent/quadrivalent high dose IIV, adjuvanted IIV, or RIV
(U.S.-licensed, or similar in formulation/manufacture to U.S.-licensed)
Comparators: Other trivalent or quadrivalent influenza vaccine
(U.S.-licensed, or similar in formulation/manufacture to U.S.-licensed)
Non-influenza control vaccine
Placebo
No vaccine
Planned Systematic Review/Meta-analysis--Summary
Outcomes: (To be finalized early November)
Efficacy/Effectiveness
–
–
–
–
–
–
–
–
All influenza -- A and B
(sub-analysis stratified by virus type and subtype as feasible)
Influenza-associated outpatient/emergency visits
Influenza-associated hospitalizations
Influenza-associated deaths
Safety
Systemic and injection site adverse events
Serious adverse events
Guillain-Barre syndrome
Severe hypersensitivity or anaphylaxis
Planned Systematic Review/Meta-analysis--Summary
Inclusion/Exclusion Criteria
 Peer-reviewed literature; no language restriction
 Publication dates from 1990 forward
 Include:
–
–
–
–
–
–
–
–
–
Randomized studies (including cluster-randomized)
Retrospective case-control and cohort studies
Prospective cohort studies
 Exclude:
Case series, case reports, registry reports without comparator information.
Studies/data on vaccines not licensed in the United States
Animal studies
Studies/data for which entire population falls outside of designated age range 
Duplicate reports
Interim reports superseded by final reports
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